Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment

Although direct‐acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection have demonstrated high rates of sustained virologic response, virologic failure may still occur, potentially leading to the emergence of viral resistance, which can decrease the effectiveness of subsequent...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology
Main Authors: Poordad, Fred, Felizarta, Franco, Asatryan, Armen, Sulkowski, Mark S., Reindollar, Robert W., Landis, Charles S., Gordon, Stuart C., Flamm, Steven L., Fried, Michael W., Bernstein, David E., Lin, Chih‐Wei, Liu, Ran, Lovell, Sandra S., Ng, Teresa I., Kort, Jens, Mensa, Federico J.
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2017
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5573922/
https://ncbi.nlm.nih.gov/pubmed/28128852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.29081
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items